Reversal of transfusion dependence by tumor necrosis factor inhibitor treatment in a patient with concurrent rheumatoid arthritis and primary myelofibrosis

Journal of Clinical Rheumatology

Volumn 17, Issue 4, 2011, Pages 211-213

  Ong, Anderson ^a   Quach, Hang ^a   Leech, Michelle ^a  

^a MONASH MEDICAL CENTRE   (Australia)

Author keywords

Anemia; Cytopenia; Myelofibrosis; Rheumatoid arthritis; Thrombocytopenia; TNF inhibitor

Indexed keywords

ADALIMUMAB; DEFEROXAMINE; HYDROXYCHLOROQUINE; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADULT; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CASE REPORT; COMORBIDITY; DRUG DOSE INCREASE; DRUG WITHDRAWAL; HUMAN; LOW DRUG DOSE; MALE; MYELOFIBROSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANEMIA; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; BLOOD TRANSFUSION; COMORBIDITY; HUMANS; MALE; MIDDLE AGED; PRIMARY MYELOFIBROSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; WITHHOLDING TREATMENT;

EID: 80051798351     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0b013e31821c7ef6     Document Type: Article

References (15)

1. Johnson RA, Waddelow TA, Caro J, et al. Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood. 1989;74:130-138. (Pubitemid 19187420)
2. Blick M, Sherwin SA, Rosenblum M, et al. Phase 1 study of recombinant tumor necrosis factor in cancer patients. Cancer Res. 1987;47:2986-2989. (Pubitemid 17113448)
3. Papadaki HA, Kritikos HD, Valatas V, et al. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy. Blood. 2002;100:474-482. (Pubitemid 34761109)
4. Papadaki HA, Kritikos HD, Gemetzi C, et al. Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor alphaYmediated effect. Blood. 2002;99:1610-1619. (Pubitemid 34533033)
5. Steensma DP, Mesa RA, Li C-Y, et al. Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study. Blood. 2002;99:2252-2254. (Pubitemid 34525516)
6. Deeg HJ, Gotlib J, Beckham C, et al. Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study. Leukemia. 2002;16:162-164. (Pubitemid 34145131)
7. Tsimberidou AM, Thomas D, O'Brien S, et al. Recombinant human soluble tumor necrosis factor (TNF) receptor ( p75) fusion protein Enbrel in patients with refractory hematologic malignancies. Cancer Chemother Pharmacol. 2002;50:237-242. (Pubitemid 35013662)
8. Salvarani C, Baricchi R, Lasagni D, et al. Effects of desferrioxamine therapy on chronic disease anemia associated with rheumatoid arthritis. Rheumatol Int. 1996;16:45-48. (Pubitemid 26318573)
9. Wang X, Garrick MD, Yang F, et al. TNF, IFN-gamma, and endotoxin increase expression of DMT1 in bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2005;289:L24-L33. (Pubitemid 40863551)
10. Feelders RA, Vreugdenhil G, Eggermont AM, et al. Regulation of iron metabolism in the acute-phase response: interferon-gamma and tumor necrosis factor > induce hypoferraemia, ferritin production and a decrease in circulating transferrin receptors in cancer patients. Eur J Clin Invest. 1998;28:520-527. (Pubitemid 28350015)
11. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102:783-788. (Pubitemid 36917762)
12. Rusten LS, Jacobsen SE. Tumor necrosis factor-alpha directly inhibits human erythropoiesis in vitro: role of pp55 and p75 TNF receptors. Blood. 1995;85:989-996.
13. Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood. 1992;79:1987-1994.
14. Doyle MK, Rahman MU, Han C, et al. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measuresVa pooled analysis from three large multicenter, double-blind, randomized clinical trials [review]. Semin Arthritis Rheum. 2009;39:123-131.
15. Davis D, Charles PJ, Potter A, et al. Anemia of chronic disease in rheumatoid arthritis: in vivo effects of tumor necrosis factor alpha blockade. Br J Rheumatol. 1997;36:950-956.